NasdaqGS:EDITBiotechs
Editas Medicine (EDIT) Q3 Loss Improvement Tests Bearish Earnings Decline Narrative
Fresh off its FY 2025 third quarter update, Editas Medicine (EDIT) posted revenue of US$7.5 million with a basic EPS loss of US$0.28. Trailing 12 month figures show revenue of US$46.4 million and a basic EPS loss of US$2.35. Over recent quarters the company has seen revenue move from US$30.6 million in Q4 2024 to US$4.7 million in Q1 2025, US$3.6 million in Q2 2025 and US$7.5 million in Q3 2025. Basic EPS losses were US$0.55, US$0.92, US$0.63 and US$0.28 across those same periods as investors...